[5] Peptides such as AOD 9604 and retatrutide, when sold with implied therapeutic claims (e.g., fat loss, metabolic enhancement), may legally constitute unlicensed medicinal products, regardless of how they are labelled by suppliers
doi: 10.1016/j.dld.2007.09.009
[DOI] [PubMed] [Google Scholar] 3.Wilding JPH, Batterham RL, Calanna S, et al
Tras la rpida expansin clnica de semaglutida y, posteriormente, de tirzepatida, contamos con evidencia slida sobre su eficacia en la obesidad y la DM2, as como sobre la reduccin de la masa grasa y la mejora de diferentes parmetros cardiometablicos
These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication